Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells

BMC Gastroenterol. 2015 Feb 15:15:22. doi: 10.1186/s12876-015-0248-8.

Abstract

Background: Non-alcoholic steatohepatitis (NASH) is associated with hepatic fibrogenesis. Despite well-known cholesterol-lowering action of statins, their mechanisms against NASH-mediated fibrogenesis remain unclear. This study aimed at investigating the in vitro and in vivo anti-fibrotic properties of fluvastatin (Flu).

Methods: Palmitate (PA)-induced changes in intracellular hydrogen peroxide levels in primary rat hepatocytes (PRHs) and human hepatoma cell line (HepG2) were quantified by dichlorofluorescein diacetate (DCF-DA) dye assay, whereas changes in expressions of NADPH oxidase gp91 (phox) subunit, α-smooth muscle actin (α-SMA), and NFκB p65 nuclear translocation were quantified with Western blotting. Quantitative real-time polymerase chain reaction (q-PCR) was used to investigate mRNA expressions of pro-inflammatory genes (ICAM-1, IL-6, TNF-α). Conditioned medium (CM) from PA-treated PRHs was applied to cultured rat hepatic stellate cell line, HSC-T6, with or without Flu-pretreatment for 2 h. Pro-fibrogenic gene expressions (COL1, TIMP-1, TGF-β1, α-SMA) and protein expression of α-SMA were analyzed. In vivo study using choline-deficient L-amino acid defined (CDAA) diet-induced rat NASH model was performed by randomly assigning Wistar rats (n = 28) to normal controls (n = 4), CDAA diet with vehicles, and CDAA diet with Flu (5 mg/kg or 10 mg/kg) (n = 8 each) through gavage for 4 or 8 weeks. Livers were harvested for histological, Western blot (α-SMA), and q-PCR analyses for expressions of pro-inflammatory (IL-6, iNOS, ICAM-1) and pro-fibrogenic (Col1, α-SMA, TIMP-1) genes.

Results: In vitro, Flu (1-20 μM) inhibited PA-induced free-radical production, gp91 (phox) expression, and NFκB p65 translocation in HepG2 and PRHs, while CM-induced α-SMA protein expression and pro-fibrogenic gene expressions in HSC-T6 were suppressed in Flu-pretreated cells compared to those without pretreatment. Moreover, α-SMA protein expression was significantly decreased in HSC-T6 cultured with CM from PA-Flu-treated PRHs compared to those cultured with CM from PA-treated PRHs. Flu also reduced steatosis and fibrosis scores, α-SMA protein expression, mRNA expression of pro-inflammatory and pro-fibrogenic genes in livers of CDAA rats.

Conclusions: We demonstrated PA-induced HSC activation through paracrine effect of hepatocyte in vitro that was significantly suppressed by pre-treating HSC with Flu. In vivo, Flu alleviated steatosis-induced HSC activation and hepatic fibrogenesis through mitigating inflammation and oxidative stress, suggesting possible therapeutic role of Flu against NASH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / genetics
  • Actins / metabolism
  • Animals
  • Choline / administration & dosage
  • Collagen Type I / genetics
  • Culture Media, Conditioned / pharmacology
  • Diet
  • Fatty Acids, Monounsaturated / pharmacology*
  • Fatty Acids, Monounsaturated / therapeutic use
  • Fluvastatin
  • Gene Expression / drug effects
  • Hep G2 Cells
  • Hepatic Stellate Cells / physiology*
  • Hepatocytes / drug effects*
  • Hepatocytes / physiology
  • Humans
  • Hydrogen Peroxide / metabolism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Indoles / pharmacology*
  • Indoles / therapeutic use
  • Intercellular Adhesion Molecule-1 / genetics
  • Interleukin-6 / genetics
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / prevention & control*
  • Male
  • Membrane Glycoproteins / metabolism
  • NADPH Oxidase 2
  • NADPH Oxidases / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / pathology
  • Oxidative Stress / drug effects
  • Palmitic Acid / pharmacology
  • Paracrine Communication / drug effects*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Transcription Factor RelA / metabolism
  • Transforming Growth Factor beta1 / pharmacology
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • ACTA2 protein, human
  • Actins
  • Collagen Type I
  • Culture Media, Conditioned
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Interleukin-6
  • Membrane Glycoproteins
  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinase-1
  • Transcription Factor RelA
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • smooth muscle actin, rat
  • Intercellular Adhesion Molecule-1
  • Palmitic Acid
  • Fluvastatin
  • Hydrogen Peroxide
  • Nitric Oxide Synthase Type II
  • CYBB protein, human
  • Cybb protein, rat
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Choline